Literature DB >> 7639013

Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.

S J Cryz1, J O Que, A S Cross, E Fürer.   

Abstract

A 12-valent Escherichia coli O-polysaccharide (O-PS)-toxin A conjugate vaccine was formulated. Nonpyrogenic, low-molecular-weight O-PS was derived from lipopolysaccharides (LPS) of the following serotypes: O1,O2,O4,O6,O7,O8,O12, O15,O16,O18,O25, and O75. Individual O-PS were covalently coupled to Pseudomonas aeruginosa toxin A using adipic acid dihydrazide as a spacer molecule and carbodiimide as a coupling agent. On a weight basis, the final multivalent vaccine was composed of 43% O-PS and 57% toxin A. The vaccine was nontoxic nad nonpyrogenic in anti-LPS immunoglobulin G (IgG) antibody titers. When passively transferred to mice, immune rabbit IgG conferred statistically significant (p < 0.05) protection against a challenge with 9 of the 12 vaccine serotypes. For two serotypes, although the mortality rate declined by > or 50% in the passively immunized versus the control group, the difference did not reach statistical significance. The degree of protection provided by passively transferred IgG was influenced by both the anti-LPS antibody levels in the IgG preparation and the virulence of the challenge strain. Active immunization of mice with either conjugate vaccine or killed E. coli whole cells did not confer protection. This was most probably due to the fact that these antigens induced a meagre anti-LPS IgG antibody response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639013     DOI: 10.1016/0264-410x(94)00009-c

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   4.169


  9 in total

Review 1.  Meningococcal glycoconjugate vaccines.

Authors:  Roberto Gasparini; Donatella Panatto
Journal:  Hum Vaccin       Date:  2011-02-01

2.  Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.

Authors:  E Bennett-Guerrero; T J McIntosh; G R Barclay; D S Snyder; R J Gibbs; M G Mythen; I R Poxton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

3.  Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.

Authors:  Simone Nicolardi; Renzo Danuser; Viktoria Dotz; Elena Domínguez-Vega; Ali Al Kaabi; Michel Beurret; Chakkumkal Anish; Manfred Wuhrer
Journal:  Anal Chem       Date:  2022-03-16       Impact factor: 6.986

4.  Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections.

Authors:  Laurent Chorro; Zhenghui Li; Ling Chu; Suddham Singh; Jianxin Gu; Jin-Hwan Kim; Kaushik Dutta; Rosalind Pan; Srinivas Kodali; Duston Ndreu; Axay Patel; Julio C Hawkins; Chris Ponce; Natalie Silmon de Monerri; David Keeney; Arthur Illenberger; C Hal Jones; Lubomira Andrew; Jason Lotvin; A Krishna Prasad; Isis Kanevsky; Kathrin U Jansen; Annaliesa S Anderson; Robert G K Donald
Journal:  Infect Immun       Date:  2022-03-21       Impact factor: 3.609

5.  Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice.

Authors:  Arun Naini; Max Peter Bartetzko; Someswara Rao Sanapala; Felix Broecker; Victoria Wirtz; Marilda P Lisboa; Sharavathi G Parameswarappa; Daniel Knopp; Jessica Przygodda; Matthias Hakelberg; Rosalind Pan; Axay Patel; Laurent Chorro; Arthur Illenberger; Christopher Ponce; Srinivas Kodali; Jacqueline Lypowy; Annaliesa S Anderson; Robert G K Donald; Arne von Bonin; Claney L Pereira
Journal:  JACS Au       Date:  2022-08-31

Review 6.  Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.

Authors:  Peter Klein Klouwenberg; Louis Bont
Journal:  Clin Dev Immunol       Date:  2008

Review 7.  Anti-endotoxin vaccines: back to the future.

Authors:  Alan S Cross
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

8.  Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.

Authors:  Megumi Inoue; Tetsuro Ogawa; Hiroshi Tamura; Yosuke Hagiwara; Yuki Saito; Darren Abbanat; Germie van den Dobbelsteen; Peter Hermans; Stefan Thoelen; Jan Poolman; Patricia Ibarra de Palacios
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

Review 9.  Targeting the Sugary Armor of Klebsiella Species.

Authors:  L Ponoop Prasad Patro; Thenmalarchelvi Rathinavelan
Journal:  Front Cell Infect Microbiol       Date:  2019-11-08       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.